STAT+: Pharmalittle: Biogen yanks Alzheimer’s paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales
Top of the morning to you, and a fine one, it is. Delicious cool breezes and clear, blue skies are enveloping the Pharmalot campus this morning. One would never know a stubborn pandemic is lurking outside. But it is. And so, we interrupt our usual greeting for a public service announcement: a vaccine is only a shot away. Now back to our regularly scheduled line up of brewing cups of stimulation and foraging for items of interest. And of course, serving up tidbits. Hope your day is productive and, as always, stay safe…
Biogen (BIIB) recently submitted a paper to JAMA, that analyzed results from the clinical trials of its new Alzheimer’s drug, Aduhelm, but later withdrew the paper because the journal considered rejecting it unless edits were made, Axios reports. Biogen says “JAMA did not reject the publication. Biogen withdrew the publication from JAMA and decided to pursue other publication opportunities.” Drug makers almost always publish study results in a peer-reviewed journal before obtaining FDA approval, but Biogen still has not done so for Aduhelm.
Continue to STAT+ to read the full story…
